173 related articles for article (PubMed ID: 31405847)
21. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
22. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Wang Z; Yin M; Chu P; Lou M
Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
[TBL] [Abstract][Full Text] [Related]
23. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
[TBL] [Abstract][Full Text] [Related]
27. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
28. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
32. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
Zhang C; Yan Z; Painter CL; Zhang Q; Chen E; Arango ME; Kuszpit K; Zasadny K; Hallin M; Hallin J; Wong A; Buckman D; Sun G; Qiu M; Anderes K; Christensen JG
Clin Cancer Res; 2009 Jul; 15(14):4630-40. PubMed ID: 19584159
[TBL] [Abstract][Full Text] [Related]
33. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
[TBL] [Abstract][Full Text] [Related]
34. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
35. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
36. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Dilly A; Honick BD; Lee YJ; Bartlett DL; Choudry HA
Cancer Med; 2020 Mar; 9(5):1753-1767. PubMed ID: 31958897
[TBL] [Abstract][Full Text] [Related]
37. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Lücking U; Wortmann L; Wengner AM; Lefranc J; Lienau P; Briem H; Siemeister G; Bömer U; Denner K; Schäfer M; Koppitz M; Eis K; Bartels F; Bader B; Bone W; Moosmayer D; Holton SJ; Eberspächer U; Grudzinska-Goebel J; Schatz C; Deeg G; Mumberg D; von Nussbaum F
J Med Chem; 2020 Jul; 63(13):7293-7325. PubMed ID: 32502336
[TBL] [Abstract][Full Text] [Related]
38. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
[TBL] [Abstract][Full Text] [Related]
39. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
40. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
